MiCo Co., Ltd. Amends Trinity Biotech Stake, Ownership Details Updated

TL;DR

**MiCo Co., Ltd. just updated its ownership details in Trinity Biotech, watch for potential strategic moves.**

AI Summary

MiCo Co., Ltd. has filed an amendment to its Schedule 13D, indicating a change in its beneficial ownership of Trinity Biotech plc's Class 'A' Ordinary Shares. The filing, dated December 20, 2023, updates information regarding MiCo's stake in Trinity Biotech. This matters to investors because significant changes in ownership by large entities like MiCo can signal shifts in corporate control or strategic direction, potentially impacting stock valuation and future company performance.

Why It Matters

This filing updates the public record on a significant shareholder's position, which can influence market perception and potentially signal future corporate actions or strategic shifts for Trinity Biotech.

Risk Assessment

Risk Level: medium — Changes in major shareholder filings can introduce uncertainty regarding future corporate governance or strategic direction, posing a medium risk to current investors.

Analyst Insight

Investors should monitor future filings from MiCo Co., Ltd. for any further changes in their stake or stated intentions, as these could signal strategic shifts for Trinity Biotech plc.

Key Players & Entities

• MiCo Co., Ltd. (company) — the filing entity and beneficial owner
• Trinity Biotech plc (company) — the subject company whose shares are being reported
• Seonkyu Jeon (person) — Director and Chairman of MiCo Co., Ltd., authorized to receive notices
• Jeongseok Jay Yu, Esq. (person) — contact at Foley Hoag LLP for legal notices
• Daniel S. Clevenger, Esq. (person) — contact at Foley Hoag LLP for legal notices

FAQ

Key Financial Figures

• $0.0109 — Class A Ordinary Shares, par value U.S. $0.0109 per share (the Ordinary Shares ), of Tr

Filing Documents

• d620462dsc13da.htm (SC 13D/A) — 38KB
• d620462dex996.htm (EX-99.6) — 108KB
• d620462dex997.htm (EX-99.7) — 3KB
• 0001193125-24-000693.txt ( ) — 150KB

From the Filing

SC 13D/A 1 d620462dsc13da.htm SC 13D/A SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Trinity Biotech plc (Name of Issuer) Class A Ordinary Shares (Title of Class of Securities) 896438306 (CUSIP Number) Seonkyu Jeon Director and Chairman MiCo Co., Ltd. 68, 68, Dongtansandan 2-gil Hwaseong-si Gyeonggi-do, 18487 Korea +82-31-612-6299 with a copy to Jeongseok Jay Yu, Esq. Daniel S. Clevenger, Esq. Foley Hoag LLP Seaport West 155 Seaport Boulevard Boston, MA 02210 617-832-1000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) December 20, 2023 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See 240.13d-7 for other parties to whom copies are sent. * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 896438306 13D Page 1 of 5 Pages 1. Names of Reporting Persons. MiCo Co., Ltd. 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) (b) 3. SEC Use Only 4. Source of Funds (See Instructions) OO 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) 6. Citizenship or Place of Organization Republic of Korea Number of Shares Beneficially Owned by Each Reporting Person With 7. Sole Voting Power 0 8. Shared Voting Power 0 9. Sole Dispositive Power 0 10. Shared Dispositive Power 0 11. Aggregate Amount Beneficially Owned by Each Reporting Person 0 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) 13. Percent of Class Represented by Amount in Row (11) 0% 14. Type of Reporting Person (See Instructions) CO CUSIP No. 896438306 Page 2 of 5 Pages The purpose of this Amendment No. 1 ( Amendment No. 1 ) to the joint statement on Schedule 13D with respect to the Class A Ordinary Shares, par value U.S. $0.0109 per share (the Ordinary Shares ), of Trinity Biotech, plc, a company organized under the laws of Ireland (the Issuer ), filed by the Reporting Person (as defined below) and MiCo IVD Holdings, LLC ( MiCo IVD ) on December 7, 2022 (such joint defined below) on December 20, 2023 and the revocation of the Joint Filing Agreement by MiCo Parent. Capitalized terms used but not defined herein have the respective meanings given to them in the Schedule 13D. 1. Paragraph (a) of Item 2 of the Schedule 13D is hereby amended and restated in full as follows: (a) This Amendment No. 1 is being filed by MiCo Co., Ltd, a limited company incorporated in South Korea ( MiCo Parent or the Reporting Person ). Certain information regarding each director and executive officer of the Reporting Person is set forth on Annex A hereto. 2. Item 4 of Schedule 13D is hereby amended by inserting the following new paragraph to the end: On December 20, 2023, MiCo Parent and MiCoBioMed Co., Ltd. ( MiCoBioMed and, together with MiCo Parent, the Sellers ), the minority owner of MiCo IVD and, together with MiCo Parent, beneficial owners of 100% of the interests of MiCo IVD, entered into a Share Purchase Agreement (the Share Purchase Agreement ) with Mainstream Holdings, Ltd. ( Mainstream ), pursuant to which the Sellers agreed to sell to Mainstream all of their equity interests in MiCo IVD for a total of 15,000,000,000 South Korean won (the MiCo IVD Sale ). The MiCo IVD Sale closed on December 21, 2023, following which time MiCo Parent has no equity interest in MiCo IVD and does not, directly or indirectly, have any equity interest in the Issuer. The foregoing description of the Share Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of such agreement, an unofficial English translation copy of which is incorporated by reference as an exhibit to this Schedule 13D. 3. Item 5 of the Schedule 13D is hereby amended and restated in full as follows: (a)-(b) The information set forth under the final para

View Full Filing

View this SC 13D/A filing on SEC EDGAR